Coca-Cola Co

KO

Equity

ISIN null / Valor 919390

New York Stock Exchange, Inc (2026-05-22)

USD 81.48+0.38%

Coca-Cola Co
UMushroom community rating:

4.27 48 votes No rating yet

NegativeNeutralPositive

About company

The Coca-Cola Company, founded on May 8, 1886, by Dr. John Pemberton in Atlanta, Georgia, has grown from its original flagship product to a diversified total beverage company. With a portfolio that spans over 200 brands, including soft drinks, water, coffee, tea, and alcohol-ready-to-drink beverages, Coca-Cola operates on a global scale, serving more than 2.2 billion servings daily across more than 200 countries and territories. The company is committed to innovation and sustainability, focusing on reducing added sugars in its drinks, enhancing recycling efforts, and implementing sustainable sourcing practices. Coca-Cola, in partnership with its bottling affiliates, employs over 700,000 individuals worldwide, contributing to economic opportunities in local communities. The company's mission is to refresh the world and make a difference, striving to offer a diverse range of beverage choices while pursuing environmentally and socially responsible business practices.

Summarized from source with an LLMView SourceSector: Consumer Non-Cyclicals

Latest Results ():

Summarized from source with an LLMView Source

Key figures

14.5%1Y

32.5%3Y

49.2%5Y

Performance

16.3%1Y

15.4%3Y

16.0%5Y

Volatility

350566 M

Market cap (USD)

8,244,441

Daily traded volume (Shares)

62.23 / 61.68

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.27

48 votes

Performance:

4.22

Innovation:

3.58

Society:

3.99

Nature:

3.68

Dylan Lai

Germany, 06 May 2026

"While the rise of GLP-1 agonists poses a strategic threat to Coca-Cola’s volume growth, the 'rebound effect' or common gastrointestinal side effects of these treatments may mitigate and delay a significant shift in consumer behavior."